BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Teclistamab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Teclistamab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06505369-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06505369)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Bispecific T-
 cell Redirectors as Part of First Line Treatment in Transplant Eligible Mu
 ltiple Myeloma Patients\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06505369
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465316-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Teclistamab: Phase 1 readout est. (NCT06465316)
DESCRIPTION:Teclistamab\, phase 1\, Multiple Myeloma.\nStudy: Testing Tecli
 stamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractor
 y Multiple Myeloma\nEstimated primary completion: 31 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06465316
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935162-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06935162)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: Teclistamab in Previously Treate
 d AL Amyloidosis\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06935162
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631208-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07631208)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: Study of the Efficacy and Safety
  of a Bispecific Antibody\, Teclistamab in Severe Rapidly Progressive Inte
 rstitial Lung Disease Associated With Anti-MDA5\nEstimated primary complet
 ion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 clistamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07631208
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05932680-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05932680)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Limited-durat
 ion Teclistamab\nEstimated primary completion: January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05932680
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079423-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07079423)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: Teclistamab in Newly Diagnosed M
 ayo Stage IIIB AL Amyloidosis\nEstimated primary completion: 31 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07079423
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030517-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:Teclistamab: Phase 4 readout est. (NCT07030517)
DESCRIPTION:Teclistamab\, phase 4\, Multiple Myeloma.\nStudy: A Study to As
 sess Safety of Teclistamab in Indian Participants With Relapsed and Refrac
 tory Multiple Myeloma\nEstimated primary completion: 12 February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07030517
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04068597-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Teclistamab: Phase 1/2 readout est. (NCT04068597)
DESCRIPTION:Teclistamab\, phase 1/2\, Multiple Myeloma.\nStudy: Study to Ev
 aluate CCS1477 (Inobrodib) in Haematological Malignancies\nEstimated prima
 ry completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04068597
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04108195-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Teclistamab: Phase 1 readout est. (NCT04108195)
DESCRIPTION:Teclistamab\, phase 1\, Multiple Myeloma.\nStudy: A Study of Su
 bcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redi
 rection Antibodies for the Treatment of Participants With Multiple Myeloma
 \nEstimated primary completion: 7 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04108195
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05572229-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05572229)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Study of Tecl
 istamab in Combination in Elderly Patients With Multiple Myeloma\nEstimate
 d primary completion: June 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05572229
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05972135-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05972135)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Outpatient Ad
 ministration of Teclistamab or Talquetamab for Multiple Myeloma\nEstimated
  primary completion: August 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05972135
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791498-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07791498)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: Teclistamab In Waldenstrom's Mac
 roglobulinemia\nEstimated primary completion: 1 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07791498
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07706205-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Teclistamab: Phase 1 readout est. (NCT07706205)
DESCRIPTION:Teclistamab\, phase 1.\nStudy: Safety and Efficacy of the Bispe
 cific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible L
 iving Donor Kidney Transplantation\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT077
 06205
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07332507-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Teclistamab: Phase 1 readout est. (NCT07332507)
DESCRIPTION:Teclistamab\, phase 1.\nStudy: Testing the Effect of Teclistama
 b on Recurrent Plasmablastic Lymphoma\nEstimated primary completion: 31 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclista
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07332507
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07657312-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07657312)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Infliximab fo
 r Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab 
 Therapy in Patients With Relapsed or Refractory Myeloma\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07657312
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948084-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06948084)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Testing the I
 nvestigational Medication Combination of Daratumumab and Teclistamab Compa
 red to the Usual Treatment (Daratumumab\, Pomalidomide\, Dexamethasone or 
 Daratumumab\, Carfilzomib\, Dexamethasone) for Patients With High-risk Mul
 tiple Myeloma Refractory or in First Relapse\nEstimated primary completion
 : 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 eclistamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06948084
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05243797-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Teclistamab: Phase 3 readout est. (NCT05243797)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: Phase 3 Study
  of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Ver
 sus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myelo
 ma as Maintenance Therapy Following Autologous Stem Cell Transplantation\n
 Estimated primary completion: April 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05243797
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06353022-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280426
DTEND;VALUE=DATE:20280427
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06353022)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Minimal Resid
 ual Disease-based Strategy With T-Cell Redirector After Treatment With Dar
 atumumab\, Bortezomib\, Lenalidomide\, and Dexamethasone (D-VRd) in Newly 
 Diagnosed Multiple Myeloma\nEstimated primary completion: 26 April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06353022
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07638683-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07638683)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: A Phase II St
 udy to Evaluate the Efficacy and Safety of Teclistamab in Combination With
  Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurren
 t Light Chain Amyloidosis (MM+AL).\nEstimated primary completion: 30 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0763868
 3
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105059-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280808
DTEND;VALUE=DATE:20280809
SUMMARY:Teclistamab: Phase 1 readout est. (NCT07105059)
DESCRIPTION:Teclistamab\, phase 1\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab and Mezigdomide in People With Multiple Myeloma\nEstimated prima
 ry completion: 8 August 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07105059
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05231629-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05231629)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Sequential Th
 erapy in Multiple Myeloma Guided by MRD Assessments\nEstimated primary com
 pletion: September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/teclistamab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05231629
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06649695-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06649695)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: A Phase II Trial of Teclistamab 
 in Participants With Previously Treated Immunoglobulin Light-chain (AL) Am
 yloidosis\nEstimated primary completion: September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06649695
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05695508-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05695508)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: GMMG-HD10 / D
 SMM-XX / 64007957MMY2003\, MajesTEC-5\nEstimated primary completion: 15 Se
 ptember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclist
 amab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05695508
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06100237-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06100237)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinica
 l and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)\nEstima
 ted primary completion: 31 December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06100237
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757412-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07757412)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab i
 n Combination With Pomalidomide Administered in Alternative Fashion in Par
 ticipants With Relapsed or Refractory Multiple Myeloma.\nEstimated primary
  completion: 1 January 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07757412
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463807-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Teclistamab: Phase 1/2 readout est. (NCT07463807)
DESCRIPTION:Teclistamab\, phase 1/2\, Multiple Myeloma.\nStudy: Testing the
  Investigational Medication Combination of Teclistamab and Pomalidomide Co
 mpared to the Usual Treatment (Carfilzomib\, Pomalidomide\, and Dexamethas
 one) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Tr
 eatment\nEstimated primary completion: 31 March 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07463807
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107529-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07107529)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Study for Fra
 il Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab
  With Teclistamab or Talquetamab.\nEstimated primary completion: April 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07107529
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581704-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Teclistamab: Phase 1 readout est. (NCT07581704)
DESCRIPTION:Teclistamab\, phase 1\, Multiple Myeloma.\nStudy: Sirolimus Pre
 -conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody E
 fficacy in Multiple Myeloma\nEstimated primary completion: 1 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07581704
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06171685-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06171685)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: MMRC Horizon 
 One: RRMM (MMRC-099)\nEstimated primary completion: 31 July 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06171685
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993675-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06993675)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Engaging T-ce
 lls to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With T
 alquetmab and Teclistamab (ROTATE)\nEstimated primary completion: August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06993675
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880601-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06880601)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Teclistamab P
 lus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple
  Myeloma\nEstimated primary completion: 1 November 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06880601
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029776-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07029776)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: MMulti-Immune
  HR\; Multi-Target Immunotherapy for High-Risk Multiple Myeloma\nEstimated
  primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07029776
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05469893-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Teclistamab: Phase 2 readout est. (NCT05469893)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: Immuno-PRISM 
 (PRecision Intervention Smoldering Myeloma)\nEstimated primary completion:
  31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclis
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05469893
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06577025-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Teclistamab: Phase 2 readout est. (NCT06577025)
DESCRIPTION:Teclistamab\, phase 2\, Multiple Myeloma.\nStudy: A Study of Di
 fferent Sequences of Cilta-cel\, Talquetamab in Combination With Daratumum
 ab and Teclistamab in Combination With Daratumumab Following Induction Wit
 h Daratumumab\, Bortezomib\, Lenalidomide and Dexamethasone in Participant
 s With Standard-risk Newly Diagnosed Multiple Myeloma\nEstimated primary c
 ompletion: 2 September 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/teclistamab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06577025
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671287-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20310214
DTEND;VALUE=DATE:20310215
SUMMARY:Teclistamab: Phase 3 readout est. (NCT07671287)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: GMMG-HD11/DSM
 M XXI/64007957MMY3010\nEstimated primary completion: 14 February 2031. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07671287
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05552222-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Teclistamab: Phase 3 readout est. (NCT05552222)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: A Study of Te
 clistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Ta
 lquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Par
 ticipants With Newly Diagnosed Multiple Myeloma\nEstimated primary complet
 ion: 30 April 2031. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 eclistamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05552222
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740486-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Teclistamab: Phase 3 readout est. (NCT07740486)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: A Study Compa
 ring Treatment With Teclistamab and Talquetamab Versus Daratumumab and Len
 alidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who
  Still Have Detectable Disease\nEstimated primary completion: June 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07740486
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110844-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07110844)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: Teclistamab-Daratumumab in AL Am
 yloidosis\nEstimated primary completion: October 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/teclistamab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07110844
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07605416-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20321106
DTEND;VALUE=DATE:20321107
SUMMARY:Teclistamab: Phase 2 readout est. (NCT07605416)
DESCRIPTION:Teclistamab\, phase 2.\nStudy: Testing an Experimental Approach
  to Treat Patients With Plasma Cell Leukemia\, The QUANTUM Trial\nEstimate
 d primary completion: 6 November 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/teclistamab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07605416
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07649525-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Teclistamab: Phase 3 readout est. (NCT07649525)
DESCRIPTION:Teclistamab\, phase 3\, Multiple Myeloma.\nStudy: Personalising
  Treatment for Myeloma Patients Based on Initial Response to NHS Treatment
  and Their Overall Fitness Level\nEstimated primary completion: June 2033.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/teclistamab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07649525
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07887984-3124@assetmemo.bio
DTSTAMP:20261121T005830Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Teclistamab: Phase 2/3 readout est. (NCT07887984)
DESCRIPTION:Teclistamab\, phase 2/3\, Multiple Myeloma.\nStudy: Comparing B
 ispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly 
 Diagnosed\, Standard Risk Multiple Myeloma\nEstimated primary completion: 
 1 August 2033. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/teclis
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07887984
URL:https://assetmemo.bio/drug/teclistamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
